<collection><source>PMC</source><date>20201214</date><key>pmc.key</key><document><id>29081</id><infon key="license">NO-CC CODE</infon><passage><infon key="article-id_doi">10.1186/1471-2156-2-1</infon><infon key="article-id_pmc">29081</infon><infon key="article-id_pmid">11178107</infon><infon key="article-id_publisher-id">1471-2156-2-1</infon><infon key="fpage">1</infon><infon key="journal-title">BMC Genetics</infon><infon key="lpage">1</infon><infon key="name_0">surname:Anderson;given-names:Michael G</infon><infon key="name_1">surname:Smith;given-names:Richard S</infon><infon key="name_2">surname:Savinova;given-names:Olga V</infon><infon key="name_3">surname:Hawes;given-names:Norman L</infon><infon key="name_4">surname:Chang;given-names:Bo</infon><infon key="name_5">surname:Zabaleta;given-names:Adriana</infon><infon key="name_6">surname:Wilpan;given-names:Robert</infon><infon key="name_7">surname:Heckenlively;given-names:John R</infon><infon key="name_8">surname:Davisson;given-names:Muriel</infon><infon key="name_9">surname:John;given-names:Simon WM</infon><infon key="section_type">TITLE</infon><infon key="type">front</infon><infon key="volume">2</infon><infon key="year">2001</infon><offset>0</offset><text>Genetic modification of glaucoma associated phenotypes between AKXD-28/Ty and DBA/2J mice</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract_title_1</infon><offset>90</offset><text>What is the background on this?</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract</infon><offset>101</offset><text>Although the molecular mechanism for glaucoma is not well understood, there are several reasons why it is so common. It is also important to identify genes that modify associated phenotypes of this disease, such as increased intraocular pressure and retinal ganglion cell death.</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract_title_1</infon><offset>1016</offset><text>What are the outcomes?</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract</infon><offset>1024</offset><text>Glaucoma is characterized by elevated intraocular pressure, retinal ganglion loss, and optic nerve excavation in mice. In AKXD-28/Ty, isa causes an iris stromal atrophy phenotype similar to DBA/2J. However, the underlying sensitivity associated with ipd (lower resolution) does not occur in reticulum or water after exposure to high-pressure eyes.</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract_title_1</infon><offset>1571</offset><text>Remarkable conclusions</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract</infon><offset>1583</offset><text>The ipd and isa mutations have an impact on the AKXD-28/Ty background, where strains that express modifier genes for pigment dispersion and susceptibility to pressure-induced cell death are identified.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">title_1</infon><offset>1830</offset><text>Glaucoma is a rare, poorly understood, and complex disease, with a high mortality rate. It is the most common cause of blindness in the world. The prognosis is poor, with a range from poor to completely blindness in up to 50% of patients, with a 10% chance of survival.

Glaucoma is a progressive disease, with the progressive loss of glaucoma occurring over time. As a result of the loss of glaucoma, patients will often be referred to a specialist in the field, with a variety of options. The most common treatment is glaucoma removal, as it is relatively easy to perform and allows for the removal of the glaucoma. However, in some cases, there</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>1841</offset><text>The majority of people worldwide are at risk of severe vision loss, including blindness, due to glaucoma, which is a group of retinal and optic nerve neuropathies. It is believed that high intraocular pressure (IOP) may cause damage, but not everyone with IOP experiences it. Additionally, the study of how low IOS can impact an individual's susceptibility to pressure-induced damage and the potential for improved treatment may indicate that more factors are involved in determining the frequency and severity of disease events such as when an outbreak conditions.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>3088</offset><text>Many mammalian species, including mice, have glaucomatous phenotypes; as such, their genes can be clinically and histologically studied throughout the path of disease, and mouse models can help identify and characterize the effects of causative genes that contribute to or hinder the progression of glucidity, as well as the genes and pathways that play a role in it. As part of our ongoing work to understand gliocoma, we are screening mice for cloning based on  markers markers by mulring as</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>4324</offset><text>The development of glaucoma in D2 mice is characterized by a harmful increase in IOP, which is further accompanied by RGC loss and optic nerve damage. This condition is linked to iris pigment dispersion (IPD), ISA, and the formation of synechial fluids that prevent water from draining into the lungs, resulting in an inherited phenotype.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>5496</offset><text>The AKXD28 inbreed is a recombinant ingr&#233;dient strain that results from an intercross between D2 and ARKR/J mice. Consequently, the genetic makeup of NKZD32 mice is quite similar to that of normal mice, except for the sex chromosome difference between males and females. This is particularly important for understanding the complex diseases that can be associated with the combination of these ipd and isa alleles, as determined by extensive ingre</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>6529</offset><text>AKXD28 mice can be used for glaucoma research due to their increased IOP and optic nerve damage, which is likely a result of genetic differences between the two strains of mice. They also have important differences in developing severe retinal damage that are more complex than D2's IPD phenotype.</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">title_1</infon><offset>7867</offset><text>Results</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>7875</offset><text>AKXD28 is a recombinant inbred mouse strain that inherited the glaucoma associated isa and ipd alleles from strain D2. To investigate the effects of these alleles in AKXD28 mice, and the potential presence of modifier loci, we examined the eyes of AKXD28 mice at ages from 2 to 28 months, as summarized in Table 1. Although the presence and severity of specific disease features were variable between mice of the same age, the disease severity clearly increased progressively with age. To ensure accurate phenotypic comparisons between the AKXD28 and D2 strains both strains were housed at the same time in the same environment and fed the same diet. The phenotype of D2 mice was previously reported and is not presented in detail here </text></passage><passage><infon key="file">T1.xml</infon><infon key="id">T1</infon><infon key="section_type">TABLE</infon><infon key="type">table_caption</infon><offset>8612</offset><text>Clinical and histological findings in AKXD-28/Ty eyes.</text></passage><passage><infon key="file">T1.xml</infon><infon key="id">T1</infon><infon key="section_type">TABLE</infon><infon key="type">table</infon><infon key="xml">&lt;?xml version="1.0" encoding="UTF-8"?&gt;
&lt;table frame="hsides" rules="groups"&gt;&lt;thead&gt;&lt;tr&gt;&lt;td/&gt;&lt;td align="left" colspan="3"&gt;&lt;bold&gt;Clin&lt;/bold&gt;&lt;/td&gt;&lt;td align="left" colspan="7"&gt;&lt;bold&gt;Histo&lt;/bold&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left"&gt;&lt;bold&gt;&lt;italic&gt;Age&lt;/italic&gt;&lt;/bold&gt;&lt;/td&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left"&gt;&lt;bold&gt;&lt;italic&gt;(months)&lt;/italic&gt;&lt;/bold&gt;&lt;/td&gt;&lt;td align="left"&gt;&lt;bold&gt;&lt;italic&gt;ISA&lt;/italic&gt;&lt;/bold&gt;&lt;/td&gt;&lt;td align="left"&gt;&lt;bold&gt;&lt;italic&gt;TRAN&lt;/italic&gt;&lt;/bold&gt;&lt;/td&gt;&lt;td align="left"&gt;&lt;bold&gt;&lt;italic&gt;DP&lt;/italic&gt;&lt;/bold&gt;&lt;/td&gt;&lt;td align="left"&gt;&lt;bold&gt;&lt;italic&gt;ISA&lt;/italic&gt;&lt;/bold&gt;&lt;/td&gt;&lt;td align="left"&gt;&lt;bold&gt;&lt;italic&gt;PAS&lt;/italic&gt;&lt;/bold&gt;&lt;/td&gt;&lt;td align="left"&gt;&lt;bold&gt;&lt;italic&gt;PS&lt;/italic&gt;&lt;/bold&gt;&lt;/td&gt;&lt;td align="left"&gt;&lt;bold&gt;&lt;italic&gt;RGCD&lt;/italic&gt;&lt;/bold&gt;&lt;/td&gt;&lt;td align="left"&gt;&lt;bold&gt;&lt;italic&gt;ONA&lt;/italic&gt;&lt;/bold&gt;&lt;/td&gt;&lt;td align="left"&gt;&lt;bold&gt;&lt;italic&gt;ONC&lt;/italic&gt;&lt;/bold&gt;&lt;/td&gt;&lt;td align="left"&gt;&lt;bold&gt;&lt;italic&gt;INL&lt;/italic&gt;&lt;/bold&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/thead&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td align="left"&gt;6-8&lt;/td&gt;&lt;td align="left"&gt;0/12&lt;/td&gt;&lt;td align="left"&gt;12/12&lt;/td&gt;&lt;td align="left"&gt;0/12&lt;/td&gt;&lt;td align="left"&gt;0/8&lt;/td&gt;&lt;td align="left"&gt;0/8&lt;/td&gt;&lt;td align="left"&gt;0/8&lt;/td&gt;&lt;td align="left"&gt;0/8&lt;/td&gt;&lt;td align="left"&gt;0/8&lt;/td&gt;&lt;td align="left"&gt;0/1&lt;/td&gt;&lt;td align="left"&gt;0/8&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td/&gt;&lt;td/&gt;&lt;td align="left"&gt;&lt;italic&gt;12 per&lt;/italic&gt;&lt;/td&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left"&gt;9-14&lt;/td&gt;&lt;td align="left"&gt;52/78&lt;/td&gt;&lt;td align="left"&gt;78/78&lt;/td&gt;&lt;td align="left"&gt;0/78&lt;/td&gt;&lt;td align="left"&gt;2/8&lt;/td&gt;&lt;td align="left"&gt;7/8&lt;/td&gt;&lt;td align="left"&gt;6/8&lt;/td&gt;&lt;td align="left"&gt;2/8&lt;/td&gt;&lt;td align="left"&gt;0/4&lt;/td&gt;&lt;td align="left"&gt;0/3&lt;/td&gt;&lt;td align="left"&gt;0/8&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td/&gt;&lt;td align="left"&gt;&lt;italic&gt;36 mi&lt;/italic&gt;&lt;/td&gt;&lt;td align="left"&gt;&lt;italic&gt;70 mi&lt;/italic&gt;&lt;/td&gt;&lt;td/&gt;&lt;td align="left"&gt;&lt;italic&gt;2 mi&lt;/italic&gt;&lt;/td&gt;&lt;td align="left"&gt;&lt;italic&gt;7 mi&lt;/italic&gt;&lt;/td&gt;&lt;td align="left"&gt;&lt;italic&gt;4 mi&lt;/italic&gt;&lt;/td&gt;&lt;td align="left"&gt;&lt;italic&gt;2 mi&lt;/italic&gt;&lt;sup&gt;b&lt;/sup&gt;&lt;/td&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td/&gt;&lt;td align="left"&gt;&lt;italic&gt;16 mod&lt;/italic&gt;&lt;/td&gt;&lt;td align="left"&gt;&lt;italic&gt;8 mo&lt;/italic&gt;&lt;/td&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td align="left"&gt;&lt;italic&gt;2 mo&lt;/italic&gt;&lt;/td&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left"&gt;15-22&lt;/td&gt;&lt;td align="left"&gt;60/60 &lt;sup&gt;a&lt;/sup&gt;&lt;/td&gt;&lt;td align="left"&gt;60/60 &lt;sup&gt;a&lt;/sup&gt;&lt;/td&gt;&lt;td align="left"&gt;0/60 &lt;sup&gt;a&lt;/sup&gt;&lt;/td&gt;&lt;td align="left"&gt;11/12&lt;/td&gt;&lt;td align="left"&gt;12/12&lt;/td&gt;&lt;td align="left"&gt;9/12&lt;/td&gt;&lt;td align="left"&gt;11/12&lt;/td&gt;&lt;td align="left"&gt;8/10&lt;/td&gt;&lt;td align="left"&gt;7/7&lt;/td&gt;&lt;td align="left"&gt;7/12&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td/&gt;&lt;td align="left"&gt;&lt;italic&gt;24 mi&lt;/italic&gt;&lt;/td&gt;&lt;td align="left"&gt;&lt;italic&gt;20 mi&lt;/italic&gt;&lt;/td&gt;&lt;td/&gt;&lt;td align="left"&gt;&lt;italic&gt;2 mi&lt;/italic&gt;&lt;/td&gt;&lt;td align="left"&gt;&lt;italic&gt;4 mi&lt;/italic&gt;&lt;/td&gt;&lt;td align="left"&gt;&lt;italic&gt;3 mi&lt;/italic&gt;&lt;/td&gt;&lt;td align="left"&gt;&lt;italic&gt;1 mi&lt;/italic&gt;&lt;sup&gt;c&lt;/sup&gt;&lt;/td&gt;&lt;td align="left"&gt;&lt;italic&gt;1 mi&lt;/italic&gt;&lt;sup&gt;c&lt;/sup&gt;&lt;/td&gt;&lt;td align="left"&gt;&lt;italic&gt;1 mo&lt;/italic&gt;&lt;sup&gt;c&lt;/sup&gt;&lt;/td&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td/&gt;&lt;td align="left"&gt;&lt;italic&gt;36 mo&lt;/italic&gt;&lt;/td&gt;&lt;td align="left"&gt;&lt;italic&gt;40 mo&lt;/italic&gt;&lt;/td&gt;&lt;td/&gt;&lt;td align="left"&gt;&lt;italic&gt;7 mo&lt;/italic&gt;&lt;/td&gt;&lt;td align="left"&gt;&lt;italic&gt;4 mo&lt;/italic&gt;&lt;/td&gt;&lt;td align="left"&gt;&lt;italic&gt;1 mo&lt;/italic&gt;&lt;/td&gt;&lt;td align="left"&gt;&lt;italic&gt;10 sev&lt;/italic&gt;&lt;sup&gt;d&lt;/sup&gt;&lt;/td&gt;&lt;td align="left"&gt;&lt;italic&gt;3 mo&lt;/italic&gt;&lt;sup&gt;d&lt;/sup&gt;&lt;/td&gt;&lt;td align="left"&gt;&lt;italic&gt;6 sev&lt;/italic&gt;&lt;sup&gt;d&lt;/sup&gt;&lt;/td&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td align="left"&gt;&lt;italic&gt;2 sev&lt;/italic&gt;&lt;/td&gt;&lt;td align="left"&gt;&lt;italic&gt;4 sev&lt;/italic&gt;&lt;/td&gt;&lt;td align="left"&gt;&lt;italic&gt;5 sev&lt;/italic&gt;&lt;/td&gt;&lt;td/&gt;&lt;td align="left"&gt;&lt;italic&gt;4 sev&lt;/italic&gt;&lt;sup&gt;d&lt;/sup&gt;&lt;/td&gt;&lt;td/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left"&gt;23-28&lt;/td&gt;&lt;td align="left"&gt;26/26&lt;/td&gt;&lt;td align="left"&gt;26/26&lt;/td&gt;&lt;td align="left"&gt;1/26&lt;/td&gt;&lt;td align="left"&gt;25/25&lt;/td&gt;&lt;td align="left"&gt;23/23&lt;/td&gt;&lt;td align="left"&gt;24/25&lt;/td&gt;&lt;td align="left"&gt;25/25&lt;/td&gt;&lt;td align="left"&gt;23/23&lt;/td&gt;&lt;td align="left"&gt;21/21&lt;/td&gt;&lt;td align="left"&gt;24/25&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td/&gt;&lt;td align="left"&gt;&lt;italic&gt;26 sev&lt;/italic&gt;&lt;/td&gt;&lt;td align="left"&gt;&lt;italic&gt;26 sev&lt;/italic&gt;&lt;/td&gt;&lt;td/&gt;&lt;td align="left"&gt;&lt;italic&gt;25 sev&lt;/italic&gt;&lt;/td&gt;&lt;td align="left"&gt;&lt;italic&gt;1 mi&lt;/italic&gt;&lt;/td&gt;&lt;td align="left"&gt;&lt;italic&gt;2 mi&lt;/italic&gt;&lt;/td&gt;&lt;td align="left"&gt;&lt;italic&gt;25 sev&lt;/italic&gt;&lt;/td&gt;&lt;td align="left"&gt;&lt;italic&gt;1 mo&lt;/italic&gt;&lt;/td&gt;&lt;td align="left"&gt;&lt;italic&gt;21 sev&lt;/italic&gt;&lt;/td&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td align="left"&gt;&lt;italic&gt;15 mo&lt;/italic&gt;&lt;/td&gt;&lt;td align="left"&gt;&lt;italic&gt;9 mo&lt;/italic&gt;&lt;/td&gt;&lt;td/&gt;&lt;td align="left"&gt;&lt;italic&gt;22 sev&lt;/italic&gt;&lt;/td&gt;&lt;td/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td align="left"&gt;&lt;italic&gt;7 sev&lt;/italic&gt;&lt;/td&gt;&lt;td align="left"&gt;&lt;italic&gt;13 sev&lt;/italic&gt;&lt;/td&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;
</infon><offset>8667</offset><text>	Clin	Histo	 	Age											 	(months)	ISA	TRAN	DP	ISA	PAS	PS	RGCD	ONA	ONC	INL	 	6-8	0/12	12/12	0/12	0/8	0/8	0/8	0/8	0/8	0/1	0/8	 			12 per									 	9-14	52/78	78/78	0/78	2/8	7/8	6/8	2/8	0/4	0/3	0/8	 		36 mi	70 mi		2 mi	7 mi	4 mi	2 mib				 		16 mod	8 mo				2 mo					 	15-22	60/60 a	60/60 a	0/60 a	11/12	12/12	9/12	11/12	8/10	7/7	7/12	 		24 mi	20 mi		2 mi	4 mi	3 mi	1 mic	1 mic	1 moc		 		36 mo	40 mo		7 mo	4 mo	1 mo	10 sevd	3 mod	6 sevd		 					2 sev	4 sev	5 sev		4 sevd			 	23-28	26/26	26/26	1/26	25/25	23/23	24/25	25/25	23/23	21/21	24/25	 		26 sev	26 sev		25 sev	1 mi	2 mi	25 sev	1 mo	21 sev		 						15 mo	9 mo		22 sev			 						7 sev	13 sev					 	</text></passage><passage><infon key="file">T1.xml</infon><infon key="id">T1</infon><infon key="section_type">TABLE</infon><infon key="type">table_foot</infon><offset>9316</offset><text>Clin = clinical, Histo = histological. a All were 15 months old; b All were 14 months old; cAll were 17 months old; dAll were 18 to 22 months old. Summary of Clinical and histological phenotypes in AKXD28 eyes. Clinical and histologic examinations were performed with different cohorts of mice. The age groups are arranged so that the overall prevalence and severity of specific disease features within each group are similar. In general, age groups are not skewed with mice of a particular age, except that the 15-22 month old group examined clinically consists of 15 month old mice. Mice less than 6 months old were characterized by normal clinical exams and histology but are not included in Table 1. The numerator indicates the number of eyes exhibiting the lesion, whereas the denominator indicates the number of eyes successfully analyzed for that lesion. The number of eyes with a finding of a specific severity is shown in italics. Phenotypes were ranked as peripheral (per), mild (mi), moderate (mo), or severe (sev) (see Materials and methods, and ref 11). Clinical abbreviations: iris stromal atrophy (ISA), iris transillumination (TRAN), and dispersed pigment (DP). Histologic abbreviations: iris stromal atrophy (ISA), peripheral anterior synechiae (PAS), posterior synechiae (PS), retinal ganglion cell depletion (RGCD), optic nerve atrophy (ONA), optic nerve cupping (ONC), and inner nuclear layer cell loss (INL). Other phenotypes not listed here include corneal neovascularization and corneal calcification that occurred in some mice, and cataracts whose incidence increased with age and that were present in all 23 month old or older mice. Despite gentle handling and great care, clinical examination induced subconjunctival hemorrhage in approximately 30-50% of AKXD28 mice. Though less frequent, spontaneous and handling induced vascular hemorrhage into the anterior chamber (hyphema) also was observed in a number of AKXD28 mice. These bleeding phenotypes occur only rarely in other strains we have studied. </text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">title_2</infon><offset>11346</offset><text>AKXD28 develop ISA but not IPD</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>11377</offset><text>Consistent with the inheritance of isa from strain D2, the iris stroma of AKXD28 mice atrophied with age (Figure 1). The first signs of ISA were small focal peripheral transillumination defects at 6 to 8 months of age. Iris stromal atrophy was histologically evident in most eyes by 15 months. ISA became progressively more severe, profoundly affecting all eyes by 23 months (Table 1, Figure 1).</text></passage><passage><infon key="file">1471-2156-2-1-1.jpg</infon><infon key="id">F1</infon><infon key="section_type">FIG</infon><infon key="type">fig_caption</infon><offset>11773</offset><text>AKXD28 develop ISA but not IPD. Representative iris phenotypes in aging AKXD28 (a-c and g, h) and D2 (d-f and i) mice are shown. Age and disease severity increase from left to right. (a, d) Two month old AKXD28 and D2 mice have a normal, complex iris morphology with clearly evident iris details including crypts, small central pupil, prominent peripupillary sphincter muscle, and pupillary ruff. (b, e) At 12 months AKXD28 (b) have iris stromal atrophy characterized by loss of iris detail, thinning of the iris stroma with exposure of the sphincter muscle (arrowhead in b), and mild transillumination defects (arrow). Dispersed pigment is not prominent in the anterior chamber. The eyes of similarly aged D2 mice (e) are more severely affected with both stromal atrophy and iris pigment dispersion. The stromal atrophy is characterized by abnormally shaped pupils, exposure of the sphincter, and loss of iris detail while the pigment dispersion is evidenced by the prominent accumulation of pigment on the front of the iris and lens (arrowheads in e). (c, f) 26 month old AKXD28 and D2 mice have marked stromal atrophy with enlarged irregular pupils, iris holes, and increased transillumination. In D2, severe loss of both iris stromal and iris pigment epithelium pigmentation due to the ISA and IPD phenotypes results in large transparent iris regions. In contrast, the AKXD28 iris remains generally pigmented due to the lack of IPD and retention of much of the pigment epithelium. Histologic analysis confirms the presence of ISA and lack of IPD in AKXD28 mice. (g) In a young AKXD28 mouse the iris has a robust stroma (S) and pigment epithelium (P) that are separated by the dilator muscle (masked by pigment in this section but located at the level of the arrows). (h) Although severity varies locally, the stroma of old AKXD28 mice is severely atrophied and almost non-existent in many places (arrow). The iris pigment epithelium (arrowhead) of old mice has a flattened morphology but remains remarkably intact considering the overall condition of the iris. (i) In old D2 mice, both the iris stroma and iris pigment epithelium are severely atrophic.</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>13930</offset><text>AKXD28 mice contain D2 derived alleles for markers Mtv23 and D6Nds3 which are located approximately 9.5 cM proximal and 5 cM distal to ipd, respectively. Additionally, AKXD-28/Ty mice contain D2 derived microsatellite markers for D6Mit207, D6Mit33, and D6Mit93 which subdivide this region and are tightly linked to ipd (data not shown). Despite inheritance of the ipd chromosomal segment from strain D2, both histological and clinical analysis of AKXD28 irides and anterior chambers failed to detect the presence of IPD at all ages examined. IPD is characterized by deterioration of the iris pigment epithelium with accumulation of dispersed pigment and pigment filled cells in the anterior chamber and on the front of the iris and lens (Figure 1e). No pigment dispersion or accumulation was observed in AKXD28 eyes (Figure 1a,b,c), and the iris pigment epithelium remained remarkably intact considering the severe iris stromal atrophy (Figure 1h). The overall condition of the iris in old AKXD28 versus old D2 mice also indicated the lack of the IPD phenotype in AKXD28. D2 mice succumb to both ISA and IPD, and develop iris atrophy that progresses to the point of transparency over most of the iris (Figure 1f). The irides of AKXD28 eyes maintain substantially greater tissue integrity and pigmentation (compare Figure 1c to f  and 1h to i).</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">title_2</infon><offset>15274</offset><text>Anterior synechiae and increased IOP in AKXD28</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>15321</offset><text>The ISA phenotype in D2 mice involves deterioration of the iris stroma and release of cellular debris into the anterior chamber. This leads to the formation of adhesions (anterior synechiae) that block aqueous humor access to its drainage pathways including the trabecular meshwork and Schlemm's canal in the iridocorneal angle. AKXD28 mice similarly develop iris stromal atrophy, anterior synechiae, and IOP elevation (Figure 2). In AKXD28, the synechiae were first evident at 9 months, and were extensive in most eyes by 15 to 22 months of age (Table 1).</text></passage><passage><infon key="file">1471-2156-2-1-2.jpg</infon><infon key="id">F2</infon><infon key="section_type">FIG</infon><infon key="type">fig_caption</infon><offset>15878</offset><text>Anterior synechiae and elevated IOP in AKXD28. (a) Young mice have normal, unobstructed iridocorneal angles. The angle has a well developed trabecular meshwork (TM, arrowhead) and open Schlemm's Canal (SC). (b) A large anterior synechia (arrow) has occluded the TM and SC in a 14 month old mouse. As shown in c (and see Table 1), the formation of synechiae is followed by IOP elevation. Two standard deviations (2 SD) above the mean IOP for 7-10 month mice is indicated by the dashed line (females) and a full line (males). Ciliary body atrophy occurs in some mice and its incidence increases with age. Although histologic analysis and IOP measurement were not performed on the same eyes, it seems likely that ciliary body atrophy explains the drop in female IOP at 19 to 21 months. Original magnifications 400X.</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>16691</offset><text>To assess the functional relationship between these morphological abnormalities and aqueous drainage, we determined the IOPs of AKXD28 mice at various ages (Figure 2). IOP increased significantly with age (P=0.0001) and pressure elevation followed a time course consistent with obstruction of aqueous humor drainage by extensive anterior synechiae formation. Although there were no obvious histologic differences between males and females, gender had a significant effect on the timing of IOP elevation (P=0.008). Among females, the mean IOP increased from 12.9 &#177; 0.3 mmHg at 7 to 10 months (when synechiae were absent or mild) to a peak value of 19.8 &#177; 1.8 mmHg at 15-18 months (when synechiae were often moderate or severe). The IOP of males showed an increase from 14.9 &#177; 0.4 mmHg at 7 to 10 months to a peak of 18.9 &#177; 1.0 mmHg at 19-21 months. The magnitudes of IOP elevation were similar to those in D2 mice.</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>17609</offset><text>Vitreous glutamate levels increase when IOP is elevated in various species and this increase is associated with RGC death. As an initial effort to assess glutamate levels in AKXD28 mice, vitreous was collected from mice of different ages and subjected to amino acid analysis. In this study, we analyzed two pools of samples from 14 month old mice and two pools of samples from 16 month old mice. Pooling was necessary due to the small volume of vitreous collected, and each pool consisted of 2 to 4 eyes (see Materials and methods). In this study, vitreous glutamate levels were 13.2 &#177; 1.7 &#956;M in 14 month old mice (when IOP is generally normal) and 29.2 &#177; 4.7 &#956;M in 16 month old mice (when IOP is often elevated).</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">title_2</infon><offset>18327</offset><text>AKXD28 develop glaucomatous neuropathy</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>18366</offset><text>AKXD28 mice develop several glaucomatous abnormalities. All retinas had a normal appearance until 14 months when mild loss of retinal ganglion cells was observed in some mice (Table 1). All mice over 18 months of age had severe ganglion cell loss both peripherally and close to the optic nerve (Figure 3, Table 1). Atrophic excavation of the optic nerve head was evident histologically and by clinical fundus examination in old but not in young mice (Figure 3, Table 1). Fundus examination was not possible in many old mice due to corneal opacities and cataracts.</text></passage><passage><infon key="file">1471-2156-2-1-3.jpg</infon><infon key="id">F3</infon><infon key="section_type">FIG</infon><infon key="type">fig_caption</infon><offset>18930</offset><text>Severe retinal and optic nerve damage in AKXD28 mice. The panels are arranged to display the progressive increase in severity from left to right. All images are from strain AKXD28 mice except for f, (D2) and g,h (AKXD28B6F1 X AKXD28, backcross N2). (a) Young AKXD28 retinas have normal morphology. The retinal ganglion cell layer (G) is continuous and 1-2 cells thick. The inner nuclear layer is approximately 5 to 6 cells thick (flanked by arrowheads). (b) Moderately affected AKXD28 retinas contain fewer retinal ganglion cells while the inner nuclear layer has some cell loss but remains relatively normal. (c) Severely affected AKXD28 retinas have very few retinal ganglion cells, the inner nuclear layer (arrow) is only 1-2 cells thick, and the total thickness of the retina is greatly reduced. Focal loss of photoreceptors is also present. The image represents the severe phenotype attained by all old AKXD28 eyes; some old eyes have even more cell loss with severe photoreceptor depletion and the remnants of retina are very thin. This severe atrophy does not occur in D2 mice (see f for a typical severe D2 retina). (d) Normal optic nerve head of a young mouse characterized by a thick nerve fiber layer entering the optic nerve (arrows), a central vessel (V), and well organized pial septae (P). (e) Advanced optic nerve excavation (arrowheads) with atrophy extending to a level external to the choroid (C). There is severe peripapillary atrophy with thinning of most retinal layers near the nerve. Although not prominent in this image, gliosis was frequently observed in severely damaged nerves. (f) Representative retina from a D2 mouse exhibiting advanced end stage retinal disease typical for that strain. Note that the inner nuclear layer is relatively unaffected and overall retinal thickness is maintained. (g) Normal fundus. (h) Glaucomatous fundus with an asymmetric and severely excavated optic nerve head (arrowhead). Peripapillary chorioretinal atrophy is also distinctly recognizable in this eye. These fundi are from backcross mice since all old AKXD28 mice had severe cataracts that made photography very difficult. The appearance of these backcross fundi closely resembles those of age matched AKXD28. Original magnifications 400X (a,b,c,f,) and 200X (d,e).</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>21213</offset><text>To further examine the progression of optic nerve damage, optic nerve cross sections from male and female mice of differing ages were analyzed (Figure 4). Optic nerve damage was detected closely following the period of increased IOP. Moderate or severe optic nerve damage was first observed in some 17 month old mice (3 of 12) and occurred in almost all 19-20 month old mice (20 of 22). Interestingly, optic nerve damage occurred earlier in females than in males. Damage was detectable in female but not male nerves at 17 months. By 19-20 months all female nerves were severely affected, whereas, approximately half of the male nerves were mildly or moderately affected (P=0.02, Chi-square) (Figure 4d).</text></passage><passage><infon key="file">1471-2156-2-1-4.jpg</infon><infon key="id">F4</infon><infon key="section_type">FIG</infon><infon key="type">fig_caption</infon><offset>21917</offset><text>Optic nerve damage in AKXD28 mice. Representative nerve sections scored as (a) mild, (b) moderate, and (c) severe are shown. (d) Nerve damage is first evident in females. At 19 to 20 months all females are severely affected whereas approximately half of the males are. Original magnifications 630X.</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">title_2</infon><offset>22216</offset><text>Retinal and optic nerve damage is more severe in AKXD28 than D2</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>22280</offset><text>Retinal damage in AKXD28 eyes was more severe than in D2 eyes (Figure 3, Table 1, and Ref.). In AKXD28 mice, IOP elevation was first noted in a few mice at 11 months and mild RGC depletion (defined here as loss of cells in the RGC layer) was initially observed at 14 months. By 18 months RGC loss was severe in all AKXD28 eyes. By contrast, D2 mice exhibit a slower and milder retinal disease following increased IOP (compare Figure 3b,c,f). In D2 mice, IOP elevation was first observed in some mice at 6 months. Mice at 18 or 19 months had no more than a moderate loss of RGCs, and only 1 of 11 mice older than 20 months had severe RGC loss. Paralleling RGC loss, optic nerve head excavation or cupping was also more severe and more frequent (P &lt; 0.0001, Chi-square) in AKXD28 than D2 mice. Optic nerve excavation was histologically evident in 27 of 27 AKXD28 mice that were 18 months or older and was typically severe (Table 1). The severe atrophy extended to a level outside of the inner nuclear layer (INL) and often outside the choroid (Figure 3e). Optic nerve excavation occurred in only 11 of 24 D2 mice that were 18 months or older. The excavation in these mice never extended deeper than the INL and was never rated severe. Clinical fundus examinations agreed with histological findings showing obvious, severe optic nerve damage in successfully analyzed old AKXD28 eyes but not in D2 eyes.</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>23680</offset><text>In addition to the typical glaucomatous changes mentioned above, an obvious loss of cells in the INL occurred in almost all AKXD28 mice 23 months old and older (Table 1, Figure 3c). In some AKXD28 mice older than 26 months, the disease progressed to affect the entire retina with substantial loss of both INL cells and photoreceptors. This is in contrast to the phenotype in D2 mice, in which INL cell loss sometimes occurred but extensive damage throughout the retina was never observed (Fig. 3f).</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">title_1</infon><offset>24179</offset><text>Discussion</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>24190</offset><text>Identifying genes that modify glaucoma associated phenotypes is likely to provide insights to mechanisms of glaucoma. An approach for identifying modifier genes is to transfer mutations that produce characterized phenotypes into different mouse strains. When the phenotypic effect of a mutation is modified upon its introduction into a new strain, crosses between the parental strains can be used to identify modifier genes. Also, the phenotypic characteristics of the new mutant strain may make it a valuable new model of the human disease. In this study, we determined the effects of the D2 derived ipd and isa alleles in the AKXD28 genetic background. We show that AKXD28 mice develop elevated IOP and glaucoma with similarities to the disease observed in D2 mice. However, there are also significant phenotypic differences between the disease in D2 and AKXD28 mice. This suggests that the genetic constitution of these strains result in differing genetic susceptibilities to glaucoma associated phenotypes and may allow the identification of modifier genes.</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">title_2</infon><offset>25252</offset><text>An AKR/J modifier(s) likely suppresses IPD in AKXD28</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>25305</offset><text>A significant difference between D2 and AKXD28 mice is the lack of an overt IPD phenotype in AKXD28, despite inheritance of the ipd allele from D2. In AKXD28, there is no obvious pigment dispersion, the iris pigment epithelium remains remarkably intact, and the irides of old mice remain pigmented. Evidence that the ipd containing chromosomal region in AKXD28 is derived from D2 includes inheritance of D2 alleles of microsatellite markers spanning an approximately 14.5 cM chromosomal region surrounding the ipd locus (delimited by the markers Mtv23 and D6Nds3). Though unlikely, the possibility of an undetected recombinational rearrangement within this region that placed an AKR/J allele of the gene that causes IPD on the AKXD28 chromosome cannot be ruled out. The presence in AKXD28 of the D2 allele of D6Mit33, which maps to the same position as ipd (25.5 cM), argues against such a rearrangement. Other explanations for the absence of an IPD phenotype in AKXD28 include: inheritance of an AKR/J modifier gene(s) that suppresses the IPD phenotype, a spontaneous reversion of the ipd mutation in AKXD28 mice, or the spontaneous occurrence and fixation of the ipd mutation in strain D2 after the derivation of the AKXD28 strain. Inheritance of an AKR/J modifier seems the most likely explanation but elucidation of the molecular nature of the ipd mutation or the mapping of a modifier gene(s) is necessary to distinguish among the possibilities.</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">title_2</infon><offset>26756</offset><text>IOP elevation occurs earlier in females</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>26796</offset><text>Female AKXD28 mice exhibit increased IOP earlier than males. Nerve damage was also first observed in females. Our clinical and histological studies identified no obvious gender differences in anterior segment pathology that account for this. It must be remembered, however, that our histological analysis accounts for a small portion of the eye and so differences in the prevalence or severity of anterior synechiae may have been missed. Further experiments including more detailed analysis of the aqueous drainage system are necessary to understand why IOP elevation occurs earlier in females than males. Interestingly, D2 females also exhibit increased IOP prior to males. Sex-specific differences in human glaucoma susceptibility have been reported in some, but not all human studies. In general, sex-specific differences in human glaucoma may be difficult to identify or interpret because of genetic differences and uncontrolled environmental factors between patients that may alter the phenotype. Since they are inbred and environment can be highly controlled, AKXD28 mice provide an experimental resource for examining the biological significance of gender for susceptibility to events that elevate IOP.</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">title_2</infon><offset>28006</offset><text>AKXD28 and D2 have different susceptibilities to pressure-induced damage</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>28079</offset><text>Overall, the progression of optic nerve and retinal disease in AKXD28 mice supports a pressure-induced etiology. Optic nerve and retinal damage were only observed at ages after high IOP was detected. Following the period of increased IOP, the retinas and optic nerves of aged AKXD28 mice undergo substantially greater damage than those of D2 mice. The damage also occurs more rapidly after IOP elevation is first detected in AKXD28 compared to D2. Strikingly, all old AKXD28 mice have severe retinal ganglion cell loss typically associated with severe optic nerve excavation, whereas, few old D2 mice have severe RGC loss and optic nerve excavation is rarely, if ever severe (defined here as extending to a level out side of the inner nuclear layer). Additionally, following initial RGC loss, most AKXD28 eyes exhibit thinning of the inner nuclear layer, and some mice older than 26 months show severe depletion of all retinal layers. Such severe and extensive retinal damage never occurs in strain D2. The RGC layer is primarily affected in most old D2 mice with the occurrence of mild inner nuclear layer cell loss and possibly, very mild photoreceptor loss in only some mice. In our studies, the occurrence of outer retinal damage was only observed in old AKXD28 eyes with late stage disease, typically several months after signs of glaucoma were evident, and was a late consequence of disease progression. Although RGCs are generally accepted to be the major cell type affected in human glaucoma, and to our knowledge INL and photoreceptor cell loss similar to that in AKXD28 has not been reported, there is evidence for INL and photoreceptor cell involvement in some human and monkey cases.</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>29775</offset><text>Both AKXD28 and D2 have similar magnitudes and durations of increased IOP, with the duration appearing to last a little longer in the more mildly affected D2 strain. The IOP distribution of D2 females is significantly elevated from 8 to 12 months of age and AKXD28 females from 15 to 18 months. Although the duration of IOP elevation in AKXD28 males is not yet characterized, female AKXD28 mice are affected more severely than D2 mice of either sex. Thus, the duration and magnitude of IOP elevation does not seem to underlie the more severe damage in AKXD28. The greater severity and speed of damage following IOP elevation in AKXD28 compared to D2 mice housed in the same environment, therefore, suggests that AKXD28 is more susceptible to pressure-induced cell death. Future experiments involving D2 and AKXD28 may allow identification of genes(s) that modulate susceptibility to pressure-induced damage and that may be relevant for human glaucoma. Identification of genes that modify pressure-induced cell death and characterization of the mechanisms by which they act will broaden the knowledge base from which informed decisions regarding patient counseling, screening, and treatment are made.</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">title_2</infon><offset>30975</offset><text>Systems that may alter susceptibility to pressure-induced damage</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>31040</offset><text>Known characteristics of the AKR/J and D2 strains offer few clues to AKXD28's increased susceptibility to pressure-induced damage and all explanatory attempts are speculative. The propensity for handling-induced hyphema and subconjunctival hemorrhage that we observe (see Table 1) in AKXD28 may indicate vascular abnormalities with relatively weak blood vessels and capillary beds. Weakened capillaries may not function optimally in the face of elevated IOP resulting in some degree of retinal ischemia that exacerbates retinal cell death. Retinal ischemia is known to affect cell viability in the INL and photoreceptor layers. Ischemia would likely invoke glutamate induced neurotoxicity.</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>31730</offset><text>Equally plausible is the possibility of differing neurotoxic responses to glutamate or differences in the ability of AKXD28 and D2 mice to buffer glutamate levels in the face of high IOP. Acting through N-methyl-D-aspartate receptors, glutamate is believed to be a potent initiator of RGC neurotoxicity and, as described here, the vitreous of at least some AKXD28 mice contains elevated glutamate concentrations when IOP is elevated. Studies with human eyes have previously reported an increase in vitreous glutamate levels from approximately 10 &#956;M in non-glaucomatous eyes to 23 &#956;M in glaucomatous eyes. Also, chronic elevation of rat vitreous glutamate levels from approximately 5-12 &#956;M to 26-34 &#956;M has previously been shown to be toxic to RGCs. The higher vitreous glutamate concentrations we observed in 16 month old (29.2 &#177; 4.7 &#956;M) compared to 14 month old (13.2 &#177; 1.7 &#956;M) AKXD28 mice would, therefore, be expected to damage the retina. Although these findings are promising and implicate glutamate in retinal neurotoxicity in AKXD28 mice, further experiments are needed to completely characterize vitreous glutamate levels and their relationship to IOP and glaucoma in this strain.</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>32926</offset><text>Molecules involved in glutamate metabolism, signaling, or buffering are interesting candidates to alter susceptibility to retinal cell death. An intriguing possibility is that AKXD28 and D2 mice have differing responses to platelet-activating factor (PAF). PAF is a biologically active phospholipid mediator. PAF acts by binding to a unique G protein coupled transmembrane receptor, PTAFR, that is broadly expressed in the eye. Relevant activities of PAF include promoting ocular hypertension and enhancing neural glutamate release. Interestingly, AKR/J airways have a strain specific hyper-responsive reaction to intravenously injected PAF. A hyper-responsiveness of AKXD28 ocular tissues to PAF or increased activity of the PTAFR receptor mediated signaling pathway could, therefore, contribute to the pronounced retinal damage through potentiating glutamate neurotoxicity.</text></passage><passage><infon key="section_type">CONCL</infon><infon key="type">title_1</infon><offset>33802</offset><text>Remarkable conclusions</text></passage><passage><infon key="section_type">CONCL</infon><infon key="type">paragraph</infon><offset>33814</offset><text>By documenting the development of a disease involving iris stromal atrophy and increased risk of retinal glaucoma in aged AKXD28 mice, we now have an additional opportunity to study the natural history of this condition in mice and use it as ill-fated animal control. Furthermore, phenotypic comparisons between the akXDe28 genome and D2 strain suggest that these modifiers may suppress pigment dispersion and increase susceptibility to pressure-induced retina damage. These findings provide combcombs into the mechanism by which they deactivating</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_1</infon><offset>34466</offset><text>Materials and methods</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>34488</offset><text>Animal husbandry</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>34505</offset><text>All experiments were performed in compliance with the Association for Research in Vision and Ophthalmology Statement for Use of Animals in Ophthalmic and Vision Research. Mice were housed in cages containing white pine bedding and covered with polyester filters. The environment was kept at 21&#176;C with a 14-h light:10-h dark cycle. Mice were fed NIH31 (6% fat) chow ad libitum, and their water was acidified to pH 2.8-3.2. All mouse strains used for this study were routinely screened for select pathogens by The Jackson Laboratory's routine surveillance program (see http://www.jax.org for specific pathogens). The mouse strains used in this study were DBA/2J (D2), AKXD-28/Ty (AKXD28), and C57BL/6J (B6). Cohorts of D2 and AKXD28 mice were housed in the same room and examined using identical protocols. The majority of AKXD28 mice were aged and analyzed at the same time as groups of D2 mice reported in a previous study. Some AKXD28 mice were subsequently analyzed and so additional D2 mice were aged and analyzed at the same time. The disease characteristics of the additional D2 mice was the same as previously described.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>35633</offset><text>Clinical examinations</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>35655</offset><text>The anterior chambers of male and female AKXD28 mice 2-27 months of age were examined with a slit-lamp biomicroscope (Haag-Streit, Mason, OH). Observed clinical phenotypes were recorded at the time of examination and rated as normal, mild, moderate, or severe based on the following criteria. Iris stromal atrophy (ISA) involves a loss of complex iris structure due to loss of iris stroma. It was ranked as mild (minor loss of iris complexity), moderate (notable lack of iris complexity and focal thinning of iris), or severe (iris lacking complex morphology and is thin, frequently with focal full thickness holes). Transillumination (TRAN) refers to light passed through the pupil and reflected off the back of the eye and through depigmented regions of the iris. TRAN was ranked as peripheral (transillumination limited to peripheral iris), mild (individual specks of transillumination across iris), moderate (individual specks and focal areas of mass transillumination), or severe (majority of iris transilluminates easily, frequently through holes). Dispersed pigment (DP) refers to clinically visible accumulations of pigment or pigment laden cells on anterior segment surfaces, most frequently observed on the lens or iris. Dispersed pigment is part of the iris pigment dispersion phenotype (IPD) that is caused by the D2 ipd allele. Fundus examination was performed with pupils dilated by a drop of 1% atropine sulfate and an indirect ophthalmoscope (American Optical, Rochester, NY) with a 60- or 90-diopter lens. Our method of fundus photography has been previously reported.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>37241</offset><text>Ocular histologic processing</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>37270</offset><text>Enucleated eyes from AKXD28 mice 2-28 months old were fixed for plastic sectioning (0.8% paraformaldehyde and 1.2% glutaraldehyde in either 0.1 M phosphate buffer, pH 7.2, or 0.1 M cacodylate buffer, pH 7.2) or for paraffin sectioning (3.2% formaldehyde, 0.7 M acetic acid, 61% ethanol) as previously described. Serial sagittal sections passing through the optic nerve were collected, stained with hematoxylin and eosin, and analyzed for pathologic changes. To control for variation with position, various phenotypes were only assessed at specific ocular locations in high quality sections. Thus, the number of eyes successfully analyzed differs with the phenotype assessed. Optic nerve cupping was only judged from sections containing central optic nerve. Optic nerve atrophy, retinal ganglion cell death, and inner nuclear layer cell loss were detectable in central sections and sections containing optic nerve that were slightly off center. Ocular lesions were rated as normal, mild, moderate, or severe using previously published criteria. Since cell counts were not performed, inner nuclear layer cell loss was only rated as affected when obvious cell loss was evident (typically at least 2 to 3 cell layers missing). One D2 eye examined histologically was excluded from the study because of the complicating presence of a large corneal ulcer accompanied by severe intraocular inflammation; this eye had a very severe retinal phenotype and severe optic nerve damage.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>38742</offset><text>Optic nerve histologic processing</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>38776</offset><text>Samples were processed as previously described. After initial fixation for 24-48 hours, optic nerves were carefully dissected, postfixed with 1% osmium tetroxide, and subsequently processed by standard procedures. A few nerves were recovered from eyes previously embedded in Historesin (Leica, Heidelberg, Germany). Cross sections were cut at a thickness of 0.5-1.0 &#956;m, stained with Toluidine Blue O, and analyzed for pathologic changes. Using this technique, the axoplasm of degenerating axons appears dark. The number of females (F) and males (M) analyzed at each age (in months) were: F13-14, n=3; M13-14, n=13; F17, n=7; M17, n=5; F19-20, n=12; M19-20, n=10. The extent of nerve damage was independently rated by 3 investigators (MGA, RSS, SWMJ) who were unaware of the animals age and of each other's classification of the tissue. A single rating for each sample was then determined by consensus, although commonly the determination was unanimous. Based on nerve morphology, damage was rated using a broad scale consisting of mild, moderate, and severe categories. Nerves estimated to contain 0-25 dark staining axons per section and limited or no gliosis were rated as mild. Normal nerves with no damage were included in this category. Nerves estimated to contain greater than 25 dark staining axons per section but still maintaining a significant portion of live axons were rated as moderate. Nerves rated as severe contained numerous damaged axons throughout the nerve, had grossly disrupted nerve morphology and sometimes contained few, if any, healthy axons. Gliosis was present in some moderately and severely damaged nerves.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>40414</offset><text>Intraocular pressure measurement</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>40447</offset><text>IOPs were measured using a microneedle system as previously described. The IOPs of B6 mice are consistent over time and so these animals were interspersed with experimental mice to ensure that calibration had not drifted and that the system was functioning optimally. The number of AKXD28 females (F) and males (M) successfully analyzed at each age were: F7-10, n=19; M7-10, n=8; F11-14, n=31; M11-14, n=21; F15-18, n=15; M15-18, n=12; F19-21, n=12; M19-21, n=10. All measurements were taken during the light-on phase of the recording room. IOP values are given as mean &#177; standard error of the mean. Reported P values are from multifactorial analysis of variance.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>41112</offset><text>Measurement of glutamate levels</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>41144</offset><text>Aged mice were euthanized and eyes removed. Vitreous was collected by inserting a pulled glass microcapillary needle inserted approximately midway between the limbus and optic nerve, and gently pressed posteriorly into the vitreous at an angle avoiding the lens and retina. This technique cleanly collected the more liquified vitreous. Pilot experiments demonstrated that it is extremely difficult to harvest the more gelatinous vitreous that is intricately associated with the retina without retinal contamination. Vitreous was collected under a dissecting microscope and any samples containing blood or other visible debris were discarded. Collected vitreous was immediately transferred to dry ice and stored at -80&#176;C until processed. Depending on the amount of vitreous collected per eye, samples from 2-4 eyes were pooled to obtain a total volume of 10-15 &#956;l of vitreous. Sample pools for female (F) and male (M) mice were collected from mice 14 and 16 months old; the number of eyes contributing to each sample pool was: F14, n=3; M14, n=3; F16, n=2; M16, n=4. Each sample pool was diluted to a final volume of 70 &#956;l with cold Beckman Li-S buffer (96.8% H2O, 1% lithium citrate, 1% thiodiglycol, 0.7% hydrogen chloride, 0.5% benzoic acid, pH 2.2), transferred to an Amicon 30 microconcentrator (Amicon Inc., Beverly, MA), and centrifuged at 16060 &#215; g for 60 minutes at 4&#176;C. The concentrator was rinsed with 25 &#956;l of Li-S buffer and centrifuged for 30 minutes. The combined filtrates were brought to a total volume of 90 &#956;l with the same buffer.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>42701</offset><text>The filtrates were divided into two and analyzed in duplicate on a Beckman 6300 Amino Acid Analyzer fitted with a 10 cm lithium column and the Beckman System Gold data collection and analysis system (Beckman Instruments Inc., Palo Alto, CA). Values for each filtrate were determined from the mean of the duplicate analyses and adjusted for the original volume of vitreous in each pool. The separation of glutamate and glutamine was achieved using Beckman's Li-A buffer (98% H2O, 1% lithium citrate, 0.5% lithium chloride, 0.5% hydrogen chloride, pH 3.0). Standard curves validating the method and ensuring accuracy over the experimental range of concentrations measured were generated using 5 samples containing known quantities of glutamate (50-1000 pmoles) and glutamine (100-3200 pmoles). Values for glutamate levels at each age are reported as mean of the female and male sample pools &#177; the standard error of the mean.</text></passage><passage><infon key="fpage">389</infon><infon key="lpage">393</infon><infon key="name_0">surname:Quigley;given-names:HA</infon><infon key="pub-id_pmid">8695555</infon><infon key="section_type">REF</infon><infon key="source">Br J Ophthalmol</infon><infon key="type">ref</infon><infon key="volume">80</infon><infon key="year">1996</infon><offset>43625</offset><text>Number of people with glaucoma worldwide.</text></passage><passage><infon key="fpage">774</infon><infon key="lpage">786</infon><infon key="name_0">surname:Quigley;given-names:HA</infon><infon key="name_1">surname:Nickells;given-names:RW</infon><infon key="name_2">surname:Kerrigan;given-names:LA</infon><infon key="name_3">surname:Pease;given-names:ME</infon><infon key="name_4">surname:Thibault;given-names:DJ</infon><infon key="name_5">surname:Zack;given-names:DJ</infon><infon key="pub-id_pmid">7706025</infon><infon key="section_type">REF</infon><infon key="source">Invest Ophthalmol Vis Sci</infon><infon key="type">ref</infon><infon key="volume">36</infon><infon key="year">1995</infon><offset>43667</offset><text>Retinal ganglion cell death in experimental glaucoma and after axotomy occurs by apoptosis.</text></passage><passage><infon key="fpage">1031</infon><infon key="lpage">1035</infon><infon key="name_0">surname:Kerrigan;given-names:LA</infon><infon key="name_1">surname:Zack;given-names:DJ</infon><infon key="name_2">surname:Quigley;given-names:HA</infon><infon key="name_3">surname:Smith;given-names:SD</infon><infon key="name_4">surname:Pease;given-names:ME</infon><infon key="pub-id_pmid">9258226</infon><infon key="section_type">REF</infon><infon key="source">Arch Ophthalmol</infon><infon key="type">ref</infon><infon key="volume">115</infon><infon key="year">1997</infon><offset>43759</offset><text>TUNEL-positive ganglion cells in human primary open-angle glaucoma.</text></passage><passage><infon key="fpage">33</infon><infon key="lpage">44</infon><infon key="name_0">surname:Garcia-Valenzuela;given-names:E</infon><infon key="name_1">surname:Shareef;given-names:S</infon><infon key="name_2">surname:Walsh;given-names:J</infon><infon key="name_3">surname:Sharma;given-names:SC</infon><infon key="pub-id_pmid">7556468</infon><infon key="section_type">REF</infon><infon key="source">Exp Eye Res</infon><infon key="type">ref</infon><infon key="volume">61</infon><infon key="year">1995</infon><offset>43827</offset><text>Programmed cell death of retinal ganglion cells during experimental glaucoma.</text></passage><passage><infon key="fpage">717</infon><infon key="lpage">725</infon><infon key="name_0">surname:Shields;given-names:MB</infon><infon key="name_1">surname:Ritch;given-names:R</infon><infon key="name_2">surname:Krupin;given-names:T</infon><infon key="section_type">REF</infon><infon key="source">The Glaucomas Edited by Ritch R, Shields MB, Krupin T, vol. 2. pp. 717-725. St. Louis: Mosby;</infon><infon key="type">ref</infon><infon key="year">1996</infon><offset>43905</offset><text>Classifications of the Glaucomas.</text></passage><passage><infon key="fpage">487</infon><infon key="lpage">497</infon><infon key="pub-id_doi">10.1016/S0002-9394(98)00223-2</infon><infon key="pub-id_pmid">9780093</infon><infon key="section_type">REF</infon><infon key="source">Am J Ophthalmol</infon><infon key="type">ref</infon><infon key="volume">126</infon><infon key="year">1998</infon><offset>43939</offset><text>Collaborative Normal-Tension Glaucoma Study Group: Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures.</text></passage><passage><infon key="fpage">282</infon><infon key="lpage">294</infon><infon key="name_0">surname:Gelatt;given-names:KN</infon><infon key="name_1">surname:Brooks;given-names:DE</infon><infon key="name_2">surname:Samuelson;given-names:DA</infon><infon key="pub-id_pmid">9713788</infon><infon key="section_type">REF</infon><infon key="source">J Glaucoma</infon><infon key="type">ref</infon><infon key="volume">7</infon><infon key="year">1998</infon><offset>44150</offset><text>Comparative glaucomatology. II: The experimental glaucomas.</text></passage><passage><infon key="fpage">187</infon><infon key="lpage">201</infon><infon key="name_0">surname:Gelatt;given-names:KN</infon><infon key="name_1">surname:Brooks;given-names:DE</infon><infon key="name_2">surname:Samuelson;given-names:DA</infon><infon key="pub-id_pmid">9627859</infon><infon key="section_type">REF</infon><infon key="source">J Glaucoma</infon><infon key="type">ref</infon><infon key="volume">7</infon><infon key="year">1998</infon><offset>44210</offset><text>Comparative glaucomatology. I: The spontaneous glaucomas.</text></passage><passage><infon key="fpage">400</infon><infon key="lpage">412</infon><infon key="name_0">surname:John;given-names:SWM</infon><infon key="name_1">surname:Anderson;given-names:MG</infon><infon key="name_2">surname:Smith;given-names:RS</infon><infon key="pub-id_pmid">10604301</infon><infon key="section_type">REF</infon><infon key="source">J Glaucoma</infon><infon key="type">ref</infon><infon key="volume">8</infon><infon key="year">1999</infon><offset>44268</offset><text>Mouse genetics: a tool to help unlock the mechanisms of glaucoma.</text></passage><passage><infon key="fpage">215</infon><infon key="lpage">220</infon><infon key="name_0">surname:Paigen;given-names:K</infon><infon key="pub-id_pmid">7585036</infon><infon key="section_type">REF</infon><infon key="source">Nat Med</infon><infon key="type">ref</infon><infon key="volume">1</infon><infon key="year">1995</infon><offset>44334</offset><text>A miracle enough: the power of mice.</text></passage><passage><infon key="fpage">951</infon><infon key="lpage">962</infon><infon key="name_0">surname:John;given-names:SWM</infon><infon key="name_1">surname:Smith;given-names:RS</infon><infon key="name_2">surname:Savinova;given-names:OV</infon><infon key="name_3">surname:Hawes;given-names:NL</infon><infon key="name_4">surname:Chang;given-names:B</infon><infon key="name_5">surname:Turnbull;given-names:D</infon><infon key="name_6">surname:Davisson;given-names:M</infon><infon key="name_7">surname:Roderick;given-names:TH</infon><infon key="name_8">surname:Heckenlively;given-names:JR</infon><infon key="pub-id_pmid">9579474</infon><infon key="section_type">REF</infon><infon key="source">Invest Ophthalmol Vis Sci</infon><infon key="type">ref</infon><infon key="volume">39</infon><infon key="year">1998</infon><offset>44371</offset><text>Essential iris atrophy, pigment dispersion, and glaucoma in DBA/2J mice.</text></passage><passage><infon key="fpage">405</infon><infon key="lpage">409</infon><infon key="name_0">surname:Chang;given-names:B</infon><infon key="name_1">surname:Smith;given-names:RS</infon><infon key="name_2">surname:Hawes;given-names:NL</infon><infon key="name_3">surname:Anderson;given-names:MG</infon><infon key="name_4">surname:Zabaleta;given-names:A</infon><infon key="name_5">surname:Savinova;given-names:O</infon><infon key="name_6">surname:Roderick;given-names:TH</infon><infon key="name_7">surname:Heckenlively;given-names:JR</infon><infon key="name_8">surname:Davisson;given-names:MT</infon><infon key="name_9">surname:John;given-names:SWM</infon><infon key="pub-id_doi">10.1038/7741</infon><infon key="pub-id_pmid">10192392</infon><infon key="section_type">REF</infon><infon key="source">Nat Genet</infon><infon key="type">ref</infon><infon key="volume">21</infon><infon key="year">1999</infon><offset>44444</offset><text>Interacting loci cause severe iris atrophy and glaucoma in DBA/2J mice.</text></passage><passage><infon key="fpage">211</infon><infon key="lpage">215</infon><infon key="name_0">surname:Richter;given-names:CU</infon><infon key="name_1">surname:Richardson;given-names:TM</infon><infon key="name_2">surname:Grant;given-names:WM</infon><infon key="pub-id_pmid">3947295</infon><infon key="section_type">REF</infon><infon key="source">Arch Ophthalmol</infon><infon key="type">ref</infon><infon key="volume">104</infon><infon key="year">1986</infon><offset>44516</offset><text>Pigmentary dispersion syndrome and pigmentary glaucoma. A prospective study of the natural history.</text></passage><passage><infon key="fpage">573</infon><infon key="lpage">587</infon><infon key="name_0">surname:Kampik;given-names:A</infon><infon key="name_1">surname:Green;given-names:WR</infon><infon key="name_2">surname:Quigley;given-names:HA</infon><infon key="name_3">surname:Pierce;given-names:LH</infon><infon key="pub-id_pmid">7234938</infon><infon key="section_type">REF</infon><infon key="source">Am J Ophthalmol</infon><infon key="type">ref</infon><infon key="volume">91</infon><infon key="year">1981</infon><offset>44616</offset><text>Scanning and transmission electron microscopic studies of two cases of pigment dispersion syndrome.</text></passage><passage><infon key="fpage">384</infon><infon key="lpage">388</infon><infon key="name_0">surname:Andersen;given-names:JS</infon><infon key="name_1">surname:Pralea;given-names:AM</infon><infon key="name_2">surname:DelBono;given-names:EA</infon><infon key="name_3">surname:Haines;given-names:JL</infon><infon key="name_4">surname:Gorin;given-names:MB</infon><infon key="name_5">surname:Schuman;given-names:JS</infon><infon key="name_6">surname:Mattox;given-names:CG</infon><infon key="name_7">surname:Wiggs;given-names:JL</infon><infon key="pub-id_pmid">9076212</infon><infon key="section_type">REF</infon><infon key="source">Arch Ophthalmol</infon><infon key="type">ref</infon><infon key="volume">115</infon><infon key="year">1997</infon><offset>44716</offset><text>A gene responsible for the pigment dispersion syndrome maps to chromosome 7q35-q36.</text></passage><passage><infon key="fpage">443</infon><infon key="lpage">449</infon><infon key="name_0">surname:Zdarsky;given-names:E</infon><infon key="name_1">surname:Favor;given-names:J</infon><infon key="name_2">surname:Jackson;given-names:IJ</infon><infon key="pub-id_pmid">2245916</infon><infon key="section_type">REF</infon><infon key="source">Genetics</infon><infon key="type">ref</infon><infon key="volume">126</infon><infon key="year">1990</infon><offset>44800</offset><text>The molecular basis of brown, an old mouse mutation, and of an induced revertant to wild type.</text></passage><passage><infon key="fpage">1597</infon><infon key="lpage">1659</infon><infon key="name_0">surname:Taylor;given-names:BA</infon><infon key="section_type">REF</infon><infon key="source">Genetic Variants and Strains of the Laboratory Mouse Edited by Lyon MF, Rastan S, Brown SDM, vol. 2, 3rd ed. pp. 1597-1659. Oxford: Oxford University Press;</infon><infon key="type">ref</infon><infon key="year">1996</infon><offset>44895</offset><text>Recombinant Inbred strains.</text></passage><passage><infon key="fpage">75</infon><infon key="lpage">86</infon><infon key="name_0">surname:Milatovich;given-names:A</infon><infon key="name_1">surname:Bolger;given-names:G</infon><infon key="name_2">surname:Michaeli;given-names:T</infon><infon key="name_3">surname:Francke;given-names:U</infon><infon key="pub-id_pmid">8009369</infon><infon key="section_type">REF</infon><infon key="source">Somat Cell Mol Genet</infon><infon key="type">ref</infon><infon key="volume">20</infon><infon key="year">1994</infon><offset>44923</offset><text>Chromosome localizations of genes for five cAMP-specific phosphodiesterases in man and mouse.</text></passage><passage><infon key="fpage">566</infon><infon key="lpage">573</infon><infon key="name_0">surname:Baumann;given-names:H</infon><infon key="name_1">surname:Held;given-names:WA</infon><infon key="name_2">surname:Berger;given-names:FG</infon><infon key="pub-id_pmid">6706951</infon><infon key="section_type">REF</infon><infon key="source">J Biol Chem</infon><infon key="type">ref</infon><infon key="volume">259</infon><infon key="year">1984</infon><offset>45017</offset><text>The acute phase response of mouse liver. Genetic analysis of the major acute phase reactants.</text></passage><passage><infon key="fpage">1471</infon><infon key="lpage">1480</infon><infon key="name_0">surname:Dumont;given-names:DJ</infon><infon key="name_1">surname:Yamaguchi;given-names:TP</infon><infon key="name_2">surname:Conlon;given-names:RA</infon><infon key="name_3">surname:Rossant;given-names:J</infon><infon key="name_4">surname:Breitman;given-names:ML</infon><infon key="pub-id_pmid">1630810</infon><infon key="section_type">REF</infon><infon key="source">Oncogene</infon><infon key="type">ref</infon><infon key="volume">7</infon><infon key="year">1992</infon><offset>45111</offset><text>tek, a novel tyrosine kinase gene located on mouse chromosome 4, is expressed in endothelial cells and their presumptive precursors.</text></passage><passage><infon key="fpage">239</infon><infon key="lpage">242</infon><infon key="name_0">surname:Taylor;given-names:BA</infon><infon key="name_1">surname:Reifsnyder;given-names:PC</infon><infon key="pub-id_pmid">8507976</infon><infon key="section_type">REF</infon><infon key="source">Mamm Genome</infon><infon key="type">ref</infon><infon key="volume">4</infon><infon key="year">1993</infon><offset>45244</offset><text>Typing recombinant inbred mouse strains for microsatellite markers.</text></passage><passage><infon key="fpage">620</infon><infon key="lpage">624</infon><infon key="name_0">surname:Cornall;given-names:RJ</infon><infon key="name_1">surname:Friedman;given-names:JM</infon><infon key="name_2">surname:Todd;given-names:JA</infon><infon key="pub-id_pmid">1450512</infon><infon key="section_type">REF</infon><infon key="source">Mamm Genome</infon><infon key="type">ref</infon><infon key="volume">3</infon><infon key="year">1992</infon><offset>45312</offset><text>Mouse microsatellites from a flow-sorted 4:6 Robertsonian chromosome.</text></passage><passage><infon key="fpage">4568</infon><infon key="lpage">4572</infon><infon key="name_0">surname:Lee;given-names:BK</infon><infon key="name_1">surname:Eicher;given-names:EM</infon><infon key="pub-id_pmid">2166832</infon><infon key="section_type">REF</infon><infon key="source">J Virol</infon><infon key="type">ref</infon><infon key="volume">64</infon><infon key="year">1990</infon><offset>45382</offset><text>Segregation patterns of endogenous mouse mammary tumor viruses in five recombinant inbred strain sets.</text></passage><passage><infon key="fpage">299</infon><infon key="lpage">305</infon><infon key="name_0">surname:Dreyer;given-names:EB</infon><infon key="name_1">surname:Zurakowski;given-names:D</infon><infon key="name_2">surname:Schumer;given-names:RA</infon><infon key="name_3">surname:Podos;given-names:SM</infon><infon key="name_4">surname:Lipton;given-names:SA</infon><infon key="pub-id_pmid">8600890</infon><infon key="section_type">REF</infon><infon key="source">Arch Ophthalmol</infon><infon key="type">ref</infon><infon key="volume">114</infon><infon key="year">1996</infon><offset>45485</offset><text>Elevated glutamate levels in the vitreous body of humans and monkeys with glaucoma.</text></passage><passage><infon key="fpage">1618</infon><infon key="lpage">1624</infon><infon key="name_0">surname:Vorwerk;given-names:CK</infon><infon key="name_1">surname:Lipton;given-names:SA</infon><infon key="name_2">surname:Zurakowski;given-names:D</infon><infon key="name_3">surname:Hyman;given-names:BT</infon><infon key="name_4">surname:Sabel;given-names:BA</infon><infon key="name_5">surname:Dreyer;given-names:EB</infon><infon key="pub-id_pmid">8675405</infon><infon key="section_type">REF</infon><infon key="source">Invest Ophthalmol Vis Sci</infon><infon key="type">ref</infon><infon key="volume">37</infon><infon key="year">1996</infon><offset>45569</offset><text>Chronic low-dose glutamate is toxic to retinal ganglion cells. Toxicity blocked by memantine.</text></passage><passage><infon key="fpage">3483</infon><infon key="lpage">3493</infon><infon key="name_0">surname:Sucher;given-names:NJ</infon><infon key="name_1">surname:Lipton;given-names:SA</infon><infon key="name_2">surname:Dreyer;given-names:EB</infon><infon key="pub-id_doi">10.1016/S0042-6989(97)00047-3</infon><infon key="pub-id_pmid">9425525</infon><infon key="section_type">REF</infon><infon key="source">Vision Res</infon><infon key="type">ref</infon><infon key="volume">37</infon><infon key="year">1997</infon><offset>45663</offset><text>Molecular basis of glutamate toxicity in retinal ganglion cells.</text></passage><passage><infon key="fpage">631</infon><infon key="lpage">639</infon><infon key="name_0">surname:Dietrich;given-names:WF</infon><infon key="name_1">surname:Lander;given-names:ES</infon><infon key="name_2">surname:Smith;given-names:JS</infon><infon key="name_3">surname:Moser;given-names:AR</infon><infon key="name_4">surname:Gould;given-names:KA</infon><infon key="name_5">surname:Luongo;given-names:C</infon><infon key="name_6">surname:Borenstein;given-names:N</infon><infon key="name_7">surname:Dove;given-names:W</infon><infon key="pub-id_pmid">8242739</infon><infon key="section_type">REF</infon><infon key="source">Cell</infon><infon key="type">ref</infon><infon key="volume">75</infon><infon key="year">1993</infon><offset>45728</offset><text>Genetic identification of Mom-1, a major modifier locus affecting Min-induced intestinal neoplasia in the mouse.</text></passage><passage><infon key="fpage">88</infon><infon key="lpage">91</infon><infon key="name_0">surname:Cormier;given-names:RT</infon><infon key="name_1">surname:Hong;given-names:KH</infon><infon key="name_2">surname:Halberg;given-names:RB</infon><infon key="name_3">surname:Hawkins;given-names:TL</infon><infon key="name_4">surname:Richardson;given-names:P</infon><infon key="name_5">surname:Mulherkar;given-names:R</infon><infon key="name_6">surname:Dove;given-names:WF</infon><infon key="name_7">surname:Lander;given-names:ES</infon><infon key="pub-id_pmid">9288104</infon><infon key="section_type">REF</infon><infon key="source">Nat Genet</infon><infon key="type">ref</infon><infon key="volume">17</infon><infon key="year">1997</infon><offset>45841</offset><text>Secretory phospholipase Pla2g2a confers resistance to intestinal tumorigenesis.</text></passage><passage><infon key="fpage">3182</infon><infon key="lpage">3192</infon><infon key="name_0">surname:Cormier;given-names:RT</infon><infon key="name_1">surname:Bilger;given-names:A</infon><infon key="name_2">surname:Lillich;given-names:AJ</infon><infon key="name_3">surname:Halberg;given-names:RB</infon><infon key="name_4">surname:Hong;given-names:KH</infon><infon key="name_5">surname:Gould;given-names:KA</infon><infon key="name_6">surname:Borenstein;given-names:N</infon><infon key="name_7">surname:Lander;given-names:ES</infon><infon key="name_8">surname:Dove;given-names:WF</infon><infon key="pub-id_doi">10.1038/sj.onc.1203646</infon><infon key="pub-id_pmid">10918573</infon><infon key="section_type">REF</infon><infon key="source">Oncogene</infon><infon key="type">ref</infon><infon key="volume">19</infon><infon key="year">2000</infon><offset>45921</offset><text>The Mom1AKR intestinal tumor resistance region consists of Pla2g2a and a locus distal to D4Mit64.</text></passage><passage><infon key="fpage">1327</infon><infon key="lpage">1337</infon><infon key="name_0">surname:Cox;given-names:GA</infon><infon key="name_1">surname:Mahaffey;given-names:CL</infon><infon key="name_2">surname:Frankel;given-names:WN</infon><infon key="pub-id_pmid">9883726</infon><infon key="section_type">REF</infon><infon key="source">Neuron</infon><infon key="type">ref</infon><infon key="volume">21</infon><infon key="year">1998</infon><offset>46019</offset><text>Identification of the mouse neuromuscular degeneration gene and mapping of a second site suppressor allele.</text></passage><passage><infon key="fpage">1599</infon><infon key="lpage">1604</infon><infon key="name_0">surname:Obata;given-names:M</infon><infon key="name_1">surname:Nishimori;given-names:H</infon><infon key="name_2">surname:Ogawa;given-names:K</infon><infon key="name_3">surname:Lee;given-names:GH</infon><infon key="pub-id_pmid">8895504</infon><infon key="section_type">REF</infon><infon key="source">Oncogene</infon><infon key="type">ref</infon><infon key="volume">13</infon><infon key="year">1996</infon><offset>46127</offset><text>Identification of the Par2 (Pulmonary adenoma resistance) locus on mouse chromosome 18, a major genetic determinant for lung carcinogen resistance in BALB/cByJ mice.</text></passage><passage><infon key="fpage">719</infon><infon key="lpage">724</infon><infon key="name_0">surname:Letts;given-names:VA</infon><infon key="name_1">surname:Schork;given-names:NJ</infon><infon key="name_2">surname:Copp;given-names:AJ</infon><infon key="name_3">surname:Bernfield;given-names:M</infon><infon key="name_4">surname:Frankel;given-names:WN</infon><infon key="pub-id_doi">10.1006/geno.1995.9946</infon><infon key="pub-id_pmid">8575765</infon><infon key="section_type">REF</infon><infon key="source">Genomics</infon><infon key="type">ref</infon><infon key="volume">29</infon><infon key="year">1995</infon><offset>46293</offset><text>A curly-tail modifier locus, mct1, on mouse chromosome 17.</text></passage><passage><infon key="fpage">1851</infon><infon key="lpage">1855</infon><infon key="name_0">surname:Dielemans;given-names:I</infon><infon key="name_1">surname:Vingerling;given-names:JR</infon><infon key="name_2">surname:Wolfs;given-names:RC</infon><infon key="name_3">surname:Hofman;given-names:A</infon><infon key="name_4">surname:Grobbee;given-names:DE</infon><infon key="name_5">surname:de Jong;given-names:PT</infon><infon key="pub-id_pmid">7800368</infon><infon key="section_type">REF</infon><infon key="source">Ophthalmology</infon><infon key="type">ref</infon><infon key="volume">101</infon><infon key="year">1994</infon><offset>46352</offset><text>The prevalence of primary open-angle glaucoma in a population-based study in The Netherlands. The Rotterdam Study.</text></passage><passage><infon key="fpage">2172</infon><infon key="lpage">2177</infon><infon key="name_0">surname:Kahn;given-names:HA</infon><infon key="name_1">surname:Milton;given-names:RC</infon><infon key="pub-id_pmid">7447769</infon><infon key="section_type">REF</infon><infon key="source">Arch Ophthalmol</infon><infon key="type">ref</infon><infon key="volume">98</infon><infon key="year">1980</infon><offset>46467</offset><text>Alternative definitions of open-angle glaucoma. Effect on prevalence and associations in the Framingham eye study.</text></passage><passage><infon key="fpage">1661</infon><infon key="lpage">1669</infon><infon key="name_0">surname:Mitchell;given-names:P</infon><infon key="name_1">surname:Smith;given-names:W</infon><infon key="name_2">surname:Attebo;given-names:K</infon><infon key="name_3">surname:Healey;given-names:PR</infon><infon key="pub-id_pmid">8874440</infon><infon key="section_type">REF</infon><infon key="source">Ophthalmology</infon><infon key="type">ref</infon><infon key="volume">103</infon><infon key="year">1996</infon><offset>46582</offset><text>Prevalence of open-angle glaucoma in Australia. The Blue Mountains Eye Study.</text></passage><passage><infon key="fpage">1499</infon><infon key="lpage">1504</infon><infon key="name_0">surname:Klein;given-names:BE</infon><infon key="name_1">surname:Klein;given-names:R</infon><infon key="name_2">surname:Sponsel;given-names:WE</infon><infon key="name_3">surname:Franke;given-names:T</infon><infon key="name_4">surname:Cantor;given-names:LB</infon><infon key="name_5">surname:Martone;given-names:J</infon><infon key="name_6">surname:Menage;given-names:MJ</infon><infon key="pub-id_pmid">1454314</infon><infon key="section_type">REF</infon><infon key="source">Ophthalmology</infon><infon key="type">ref</infon><infon key="volume">99</infon><infon key="year">1992</infon><offset>46660</offset><text>Prevalence of glaucoma. The Beaver Dam Eye Study.</text></passage><passage><infon key="fpage">918</infon><infon key="lpage">924</infon><infon key="name_0">surname:Leske;given-names:MC</infon><infon key="name_1">surname:Connell;given-names:AM</infon><infon key="name_2">surname:Wu;given-names:SY</infon><infon key="name_3">surname:Hyman;given-names:LG</infon><infon key="name_4">surname:Schachat;given-names:AP</infon><infon key="pub-id_pmid">7605285</infon><infon key="section_type">REF</infon><infon key="source">Arch Ophthalmol</infon><infon key="type">ref</infon><infon key="volume">113</infon><infon key="year">1995</infon><offset>46710</offset><text>Risk factors for open-angle glaucoma. The Barbados Eye Study.</text></passage><passage><infon key="fpage">697</infon><infon key="lpage">706</infon><infon key="name_0">surname:Vaegan</infon><infon key="name_1">surname:Graham;given-names:SL</infon><infon key="name_2">surname:Goldberg;given-names:I</infon><infon key="name_3">surname:Buckland;given-names:L</infon><infon key="name_4">surname:Hollows;given-names:FC</infon><infon key="pub-id_pmid">7641852</infon><infon key="section_type">REF</infon><infon key="source">Exp Eye Res</infon><infon key="type">ref</infon><infon key="volume">60</infon><infon key="year">1995</infon><offset>46772</offset><text>Flash and pattern electroretinogram changes with optic atrophy and glaucoma.</text></passage><passage><infon key="fpage">45</infon><infon key="lpage">54</infon><infon key="name_0">surname:Fazio;given-names:DT</infon><infon key="name_1">surname:Heckenlively;given-names:JR</infon><infon key="name_2">surname:Martin;given-names:DA</infon><infon key="name_3">surname:Christensen;given-names:RE</infon><infon key="pub-id_pmid">3732012</infon><infon key="section_type">REF</infon><infon key="source">Doc Ophthalmol</infon><infon key="type">ref</infon><infon key="volume">63</infon><infon key="year">1986</infon><offset>46849</offset><text>The electroretinogram in advanced open-angle glaucoma.</text></passage><passage><infon key="fpage">1863</infon><infon key="lpage">1868</infon><infon key="name_0">surname:Holopigian;given-names:K</infon><infon key="name_1">surname:Seiple;given-names:W</infon><infon key="name_2">surname:Mayron;given-names:C</infon><infon key="name_3">surname:Koty;given-names:R</infon><infon key="name_4">surname:Lorenzo;given-names:M</infon><infon key="pub-id_pmid">2211032</infon><infon key="section_type">REF</infon><infon key="source">Invest Ophthalmol Vis Sci</infon><infon key="type">ref</infon><infon key="volume">31</infon><infon key="year">1990</infon><offset>46904</offset><text>Electrophysiological and psychophysical flicker sensitivity in patients with primary open-angle glaucoma and ocular hypertension.</text></passage><passage><infon key="fpage">2532</infon><infon key="lpage">2536</infon><infon key="name_0">surname:Panda;given-names:S</infon><infon key="name_1">surname:Jonas;given-names:JB</infon><infon key="pub-id_pmid">1634350</infon><infon key="section_type">REF</infon><infon key="source">Invest Ophthalmol Vis Sci</infon><infon key="type">ref</infon><infon key="volume">33</infon><infon key="year">1992</infon><offset>47034</offset><text>Decreased photoreceptor count in human eyes with secondary angle-closure glaucoma.</text></passage><passage><infon key="fpage">378</infon><infon key="lpage">385</infon><infon key="name_0">surname:Janssen;given-names:P</infon><infon key="name_1">surname:Naskar;given-names:R</infon><infon key="name_2">surname:Moore;given-names:S</infon><infon key="name_3">surname:Thanos;given-names:S</infon><infon key="name_4">surname:Thiel;given-names:HJ</infon><infon key="section_type">REF</infon><infon key="source">German J Ophthalmol</infon><infon key="type">ref</infon><infon key="volume">5</infon><infon key="year">1997</infon><offset>47117</offset><text>Evidence for glaucoma-induced horizontal cell alterations in the human retina.</text></passage><passage><infon key="fpage">235</infon><infon key="lpage">245</infon><infon key="name_0">surname:Nork;given-names:TM</infon><infon key="name_1">surname:Ver Hoeve;given-names:JN</infon><infon key="name_2">surname:Poulsen;given-names:GL</infon><infon key="name_3">surname:Nickells;given-names:RW</infon><infon key="name_4">surname:Davis;given-names:MD</infon><infon key="name_5">surname:Weber;given-names:AJ</infon><infon key="name_6">surname:Vaegan</infon><infon key="name_7">surname:Sarks;given-names:SH</infon><infon key="name_8">surname:Lemley;given-names:HL</infon><infon key="name_9">surname:Millecchia;given-names:LL</infon><infon key="pub-id_pmid">10676789</infon><infon key="section_type">REF</infon><infon key="source">Arch Ophthalmol</infon><infon key="type">ref</infon><infon key="volume">118</infon><infon key="year">2000</infon><offset>47196</offset><text>Swelling and loss of photoreceptors in chronic human and experimental glaucomas.</text></passage><passage><infon key="fpage">573</infon><infon key="lpage">582</infon><infon key="name_0">surname:Hughes;given-names:WF</infon><infon key="pub-id_pmid">1743256</infon><infon key="section_type">REF</infon><infon key="source">Exp Eye Res</infon><infon key="type">ref</infon><infon key="volume">53</infon><infon key="year">1991</infon><offset>47277</offset><text>Quantitation of ischemic damage in the rat retina.</text></passage><passage><infon key="fpage">750</infon><infon key="lpage">757</infon><infon key="name_0">surname:Kalloniatis;given-names:M</infon><infon key="pub-id_pmid">8557953</infon><infon key="section_type">REF</infon><infon key="source">J Am Optom Assoc</infon><infon key="type">ref</infon><infon key="volume">66</infon><infon key="year">1995</infon><offset>47328</offset><text>Amino acids in neurotransmission and disease.</text></passage><passage><infon key="fpage">1278</infon><infon key="lpage">1293</infon><infon key="name_0">surname:Wityk;given-names:RJ</infon><infon key="name_1">surname:Stern;given-names:BJ</infon><infon key="pub-id_pmid">8045148</infon><infon key="section_type">REF</infon><infon key="source">Crit Care Med</infon><infon key="type">ref</infon><infon key="volume">22</infon><infon key="year">1994</infon><offset>47374</offset><text>Ischemic stroke: today and tomorrow.</text></passage><passage><infon key="fpage">2672</infon><infon key="lpage">2678</infon><infon key="name_0">surname:Mori;given-names:M</infon><infon key="name_1">surname:Aihara;given-names:M</infon><infon key="name_2">surname:Shimizu;given-names:T</infon><infon key="pub-id_pmid">9375587</infon><infon key="section_type">REF</infon><infon key="source">Invest Ophthalmol Vis Sci</infon><infon key="type">ref</infon><infon key="volume">38</infon><infon key="year">1997</infon><offset>47411</offset><text>Localization of platelet-activating factor receptor messenger RNA in the rat eye.</text></passage><passage><infon key="fpage">1211</infon><infon key="lpage">1216</infon><infon key="name_0">surname:Clark;given-names:GD</infon><infon key="name_1">surname:Happel;given-names:LT</infon><infon key="name_2">surname:Zorumski;given-names:CF</infon><infon key="name_3">surname:Bazan;given-names:NG</infon><infon key="pub-id_pmid">1334422</infon><infon key="section_type">REF</infon><infon key="source">Neuron</infon><infon key="type">ref</infon><infon key="volume">9</infon><infon key="year">1992</infon><offset>47493</offset><text>Enhancement of hippocampal excitatory synaptic transmission by platelet-activating factor.</text></passage><passage><infon key="fpage">97</infon><infon key="lpage">105</infon><infon key="name_0">surname:Jager;given-names:GV</infon><infon key="name_1">surname:van Delft;given-names:JL</infon><infon key="name_2">surname:van Haeringen;given-names:NJ</infon><infon key="name_3">surname:Verbeij;given-names:NL</infon><infon key="name_4">surname:Braquet;given-names:P</infon><infon key="pub-id_doi">10.1016/0090-6980(93)90093-M</infon><infon key="pub-id_pmid">8424134</infon><infon key="section_type">REF</infon><infon key="source">Prostaglandins</infon><infon key="type">ref</infon><infon key="volume">45</infon><infon key="year">1993</infon><offset>47584</offset><text>Antagonist of platelet-activating factor prevents prostaglandin E2 induced ocular hypertension in rabbits.</text></passage><passage><infon key="fpage">S23</infon><infon key="lpage">34</infon><infon key="name_0">surname:Bazan;given-names:NG</infon><infon key="name_1">surname:Allan;given-names:G</infon><infon key="pub-id_pmid">9154273</infon><infon key="section_type">REF</infon><infon key="source">Surv Ophthalmol</infon><infon key="type">ref</infon><infon key="volume">41 Suppl 2</infon><infon key="year">1997</infon><offset>47691</offset><text>Signal transduction and gene expression in the eye: a contemporary view of the pro-inflammatory, anti-inflammatory and modulatory roles of prostaglandins and other bioactive lipids.</text></passage><passage><infon key="fpage">586</infon><infon key="lpage">594</infon><infon key="name_0">surname:Longphre;given-names:M</infon><infon key="name_1">surname:Kleeberger;given-names:SR</infon><infon key="pub-id_pmid">7576695</infon><infon key="section_type">REF</infon><infon key="source">Am J Respir Cell Mol Biol</infon><infon key="type">ref</infon><infon key="volume">13</infon><infon key="year">1995</infon><offset>47873</offset><text>Susceptibility to platelet-activating factor-induced airway hyperreactivity and hyperpermeability: interstrain variation and genetic control.</text></passage><passage><infon key="fpage">22</infon><infon key="name_0">surname:Hawes;given-names:NL</infon><infon key="name_1">surname:Smith;given-names:RS</infon><infon key="name_2">surname:Chang;given-names:B</infon><infon key="name_3">surname:Davisson;given-names:M</infon><infon key="name_4">surname:Heckenlively;given-names:JR</infon><infon key="name_5">surname:John;given-names:SWM</infon><infon key="pub-id_pmid">10493779</infon><infon key="section_type">REF</infon><infon key="source">Mol Vis</infon><infon key="type">ref</infon><infon key="volume">5</infon><infon key="year">1999</infon><offset>48015</offset><text>Mouse fundus photography and angiography: a catalogue of normal and mutant phenotypes.</text></passage><passage><infon key="fpage">1380</infon><infon key="lpage">1385</infon><infon key="name_0">surname:Jia;given-names:L</infon><infon key="name_1">surname:Cepurna;given-names:WO</infon><infon key="name_2">surname:Johnson;given-names:EC</infon><infon key="name_3">surname:Morrison;given-names:JC</infon><infon key="pub-id_pmid">10798653</infon><infon key="section_type">REF</infon><infon key="source">Invest Ophthalmol Vis Sci</infon><infon key="type">ref</infon><infon key="volume">41</infon><infon key="year">2000</infon><offset>48102</offset><text>Patterns of intraocular pressure elevation after aqueous humor outflow obstruction in rats.</text></passage><passage><infon key="fpage">249</infon><infon key="lpage">253</infon><infon key="name_0">surname:John;given-names:SWM</infon><infon key="name_1">surname:Hagaman;given-names:JR</infon><infon key="name_2">surname:MacTaggart;given-names:TE</infon><infon key="name_3">surname:Peng;given-names:L</infon><infon key="name_4">surname:Smithes;given-names:O</infon><infon key="pub-id_pmid">9008647</infon><infon key="section_type">REF</infon><infon key="source">Invest Ophthalmol Vis Sci</infon><infon key="type">ref</infon><infon key="volume">38</infon><infon key="year">1997</infon><offset>48194</offset><text>Intraocular pressure in inbred mouse strains.</text></passage></document></collection>